Literature DB >> 12225447

Antipsychotic use in Australia: the patients' perspective.

David Castle1, Vera Morgan, Assen Jablensky.   

Abstract

OBJECTIVE: To describe patterns of self-reported medication use in a population-based sample of people with psychotic disorders; to establish correlates with clinical variables; to determine perceived side-effect burden; and investigate patient perception of efficacy for different classes of antipsychotic agent.
METHODS: Using the Australian Low Prevalence (Psychosis) Study database we analysed patterns of psychotropic medication and examined their clinical correlates. We also determined rates of reported side-effects and perceived benefit or otherwise associated with the different antipsychotic drugs.
RESULTS: Of the 1126 persons interviewed, 88.6% were on psychotropic medication; 54.3% were using "typical" antipsychotics (24.8% in depot form), while 8.3% were on clozapine, 13.3% on risperidone, and 8.8% on olanzapine. Around 30% of women, and 20% of men, were on mood stabilizers or antidepressants. Over half of respondents were on more than one agent. Of those on only one agent, nearly 80% reported at least one side-effect; the mean number of side-effects was 3.9 for typical antipsychotics, and 3.3 for atypicals. Atypicals, notably clozapine, tended to be rated by patients as more efficacious than typicals; depot preparations, in particular, tended to be seen as unhelpful, and were associated with a higher side-effect burden.
CONCLUSIONS: This study presents an insight into patients' perception of efficacy and side-effects of antipsychotic medications. The findings have implications for clinicians, and can inform treatment options in people with psychotic disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225447     DOI: 10.1046/j.1440-1614.2002.01037.x

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  11 in total

1.  Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.

Authors:  Y-T Xiang; G S Ungvari; C U Correll; H F K Chiu; N Shinfuku
Journal:  Epidemiol Psychiatr Sci       Date:  2015-08-20       Impact factor: 6.892

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

3.  Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.

Authors:  Christopher Carswell; Amanda Wheeler; Jane Vanderpyl; Elizabeth Robinson
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.

Authors:  Taishiro Kishimoto; Sohag Sanghani; Mark J Russ; Akeem N Marsh; Joshua Morris; Suparna Basu; Majnu John; John M Kane
Journal:  Int Clin Psychopharmacol       Date:  2017-05       Impact factor: 1.659

5.  Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.

Authors:  D J Siskind; M Harris; A Phillipou; V A Morgan; A Waterreus; C Galletly; V J Carr; C Harvey; D Castle
Journal:  Epidemiol Psychiatr Sci       Date:  2016-07-18       Impact factor: 6.892

6.  Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.

Authors:  Heidi J Wehring; Sheryl Thedford; Maju Koola; Deanna L Kelly
Journal:  J Cent Nerv Syst Dis       Date:  2011-06-01

Review 7.  New roles for pharmacists in community mental health care: a narrative review.

Authors:  Maria Rubio-Valera; Timothy F Chen; Claire L O'Reilly
Journal:  Int J Environ Res Public Health       Date:  2014-10-21       Impact factor: 3.390

Review 8.  Patient and family attitudes toward schizophrenia treatment.

Authors:  Farzin Irani; Mary Dankert; Steven J Siegel
Journal:  Curr Psychiatry Rep       Date:  2004-08       Impact factor: 8.081

9.  Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications.

Authors:  M S Karthik; Nisha Warikoo; Subho Chakrabarti; Sandeep Grover; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2014-07

10.  Attitudes toward long-acting injectable antipsychotics among patients with schizophrenia in Japan.

Authors:  Norio Sugawara; Shuhei Kudo; Masamichi Ishioka; Yasushi Sato; Kazutoshi Kubo; Norio Yasui-Furukori
Journal:  Neuropsychiatr Dis Treat       Date:  2019-01-09       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.